We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
Read MoreHide Full Article
Allergan, a unit of AbbVie (ABBV - Free Report) , and Switzerland-based Molecular Partners announced that the FDA has issued a complete response letter (“CRL”) to the biologics license application (“BLA”) seeking approval for abicipar pegol. The companies evaluated abicipar pegol, a new class of custom-built protein therapeutics — DARPin, as a potential treatment for neovascular (wet) age-related macular degeneration (nAMD).
The CRL stated that the rate of intraocular inflammation observed following administration of the candidate showed an unfavorable benefit-risk ratio in nAMD patients. AbbVie is planning to discuss the CRL with the FDA to determine the appropriate next steps for abicipar pegol.
A regulatory application seeking approval for abicipar pegol similar indication is also under review in Europe. A decision is expected in the second half of 2020.
Please note that AbbVie completed the acquisition of Allergan last month for a cash-and-stock transaction approximately valued at $63 billion.
AbbVie share price has risen 9.5% this year so far against the industry’s decrease of 3.8%.
Regulatory filings for abicipar pegol were filed based on two phase III studies — SEQUOIA and CEDAR — which evaluated abicipar pegol compared with Novartis (NVS - Free Report) /Roche’s (RHHBY - Free Report) Lucentis (ranibizumab) in treatment-naive nAMD patients. Data from the studies had demonstrated that treatment with six or eight injections of abicipar pegol resulted in similar efficacy for the primary endpoint (proportion of treated patients achieving stable vision at week 52) compared to 13 injections for Lucentis.
Please note that Regeneron Pharmaceuticals' (REGN - Free Report) blockbuster anti-VEGF drug Eylea (aflibercept) injection is approved to treat patients with nAMD. However, abicipar pegol, with its quarterly dosing regimens, has the potential to reduce patient burden by lowering the frequency of injections while maintaining vision gains.
However, the path forward for abicipar pegol will be decided following AbbVie’s meeting with the FDA.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Shutterstock
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
Allergan, a unit of AbbVie (ABBV - Free Report) , and Switzerland-based Molecular Partners announced that the FDA has issued a complete response letter (“CRL”) to the biologics license application (“BLA”) seeking approval for abicipar pegol. The companies evaluated abicipar pegol, a new class of custom-built protein therapeutics — DARPin, as a potential treatment for neovascular (wet) age-related macular degeneration (nAMD).
The CRL stated that the rate of intraocular inflammation observed following administration of the candidate showed an unfavorable benefit-risk ratio in nAMD patients. AbbVie is planning to discuss the CRL with the FDA to determine the appropriate next steps for abicipar pegol.
A regulatory application seeking approval for abicipar pegol similar indication is also under review in Europe. A decision is expected in the second half of 2020.
Please note that AbbVie completed the acquisition of Allergan last month for a cash-and-stock transaction approximately valued at $63 billion.
AbbVie share price has risen 9.5% this year so far against the industry’s decrease of 3.8%.
Regulatory filings for abicipar pegol were filed based on two phase III studies — SEQUOIA and CEDAR — which evaluated abicipar pegol compared with Novartis (NVS - Free Report) /Roche’s (RHHBY - Free Report) Lucentis (ranibizumab) in treatment-naive nAMD patients. Data from the studies had demonstrated that treatment with six or eight injections of abicipar pegol resulted in similar efficacy for the primary endpoint (proportion of treated patients achieving stable vision at week 52) compared to 13 injections for Lucentis.
Please note that Regeneron Pharmaceuticals' (REGN - Free Report) blockbuster anti-VEGF drug Eylea (aflibercept) injection is approved to treat patients with nAMD. However, abicipar pegol, with its quarterly dosing regimens, has the potential to reduce patient burden by lowering the frequency of injections while maintaining vision gains.
However, the path forward for abicipar pegol will be decided following AbbVie’s meeting with the FDA.
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>